MiMedx Group (NASDAQ:MDXG) Downgraded to Buy at StockNews.com

MiMedx Group (NASDAQ:MDXG) was downgraded by investment analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday.

Other analysts have also issued reports about the stock. HC Wainwright reiterated a “buy” rating and issued a $11.00 price target on shares of MiMedx Group in a research report on Wednesday, May 1st. Craig Hallum decreased their target price on shares of MiMedx Group from $14.00 to $12.00 and set a “buy” rating on the stock in a research report on Thursday. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $11.00 target price on shares of MiMedx Group in a research report on Thursday. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has a consensus rating of “Buy” and an average price target of $12.00.

MiMedx Group Stock Performance

Shares of NASDAQ:MDXG traded down $0.21 on Monday, reaching $6.25. The company’s stock had a trading volume of 1,180,614 shares, compared to its average volume of 763,944. The stock’s 50-day moving average is $7.09 and its two-hundred day moving average is $7.43. MiMedx Group has a 52-week low of $5.57 and a 52-week high of $9.27. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.85 and a quick ratio of 2.71. The stock has a market capitalization of $922.53 million, a P/E ratio of 14.20 and a beta of 1.98.

Institutional Trading of MiMedx Group

A number of hedge funds have recently bought and sold shares of the stock. AJOVista LLC acquired a new stake in MiMedx Group in the 4th quarter valued at about $25,000. Headlands Technologies LLC acquired a new stake in MiMedx Group in the 1st quarter valued at about $27,000. Loudon Investment Management LLC acquired a new stake in MiMedx Group in the 4th quarter valued at about $105,000. Entropy Technologies LP acquired a new stake in MiMedx Group in the 1st quarter valued at about $99,000. Finally, Raymond James & Associates acquired a new stake in MiMedx Group in the 4th quarter valued at about $114,000. 79.15% of the stock is owned by institutional investors.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.